Replies to post #386946 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

WHATS 10% OF $2,500,000,000 ?

[Pharma Sleuth]

If it is Vyanese but you also have to consider Concerta and Oxy and Adderall ER and unknown #3. It's still getting you to $9b market.

And it's still only guessing at 10% market share. Concerta could have only a few comps. I took low numbers across the board to make the point.

OXY we might be first to get approved.

Why I chose 10% because it's so low but the numbers are still massive.

Based on the fact we are marketing our own drugs and we are a small lean company, we most likely can be unbelievably price competitive. That's what is happening with the current drugs I suspect.

And again, these are the known knowns and the known unknowns.

You would have to assume that Elite was done developing more drugs after these 9b market which we know that is not the case.

[The ELTP King]

Lol.

You sold at .05

I told you how stupid you were for doing that.

Elite hasn't even gotten STARTED and we're at .087

The stock is a buy.

[The ELTP King]

Clown,

- "IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product."

Vyvanse was brand name only for the market size time frame in the press release.

[The ELTP King]

Yeah you're right...............it will be more.

Here ya go: (GlobalData Graph in middle of screen)

https://www.globaldata.com/data-insights/healthcare/the-global-drug-sales-of-vyvanse-1127472/

Elite will win a slice of the pie… but it won’t be a $5 billion dollar market.

[jour_trader]

Thanks. My guess was a 50% drop in total market early on, but that was just me shooting from the hip. I’d expect even more % to shift to generic by year 3. I’d like to analyze some data to understand brand to Rx better va high level assumptions. I still expect it to be a good market for years with some initial tailwinds due to Adderall shortage challenges driving some Rx this way.